Literature DB >> 16474174

Variants at the APOA5 locus, association with carotid atherosclerosis, and modification by obesity: the Framingham Study.

Roberto Elosua1, Jose M Ordovas, L Adrienne Cupples, Chao-Qiang Lai, Serkalem Demissie, Caroline S Fox, Joseph F Polak, Philip A Wolf, Ralph B D'Agostino, Christopher J O'Donnell.   

Abstract

Genetic variation at the apolipoprotein A5 gene (APOA5) is associated with increased triglyceride concentrations, a risk factor for atherosclerosis. Carotid intimal medial thickness (IMT) is a surrogate measure of atherosclerosis burden. We sought to determine the association of common APOA5 genetic variants with carotid IMT and stenosis. A total of 2,273 Framingham Offspring Study participants underwent carotid ultrasound and had data on at least one of the five APOA5 variants (-1131T>C, -3A>G, 56C>G, IVS3+476G >A, and 1259T>C). Although none of the individual variants was significantly associated with carotid measures, the haplotype defined by the presence of the rare allele of the 56C>G variant was associated with a higher common carotid artery (CCA) IMT compared with the wild-type haplotype (0.75 vs. 0.73 mm; P < 0.05). The rare allele of each of the -1131T >C, -3A>G, IVS3+476G>A, and 1259T>C variants and the haplotype defined by the presence of the rare alleles in these four variants were each significantly associated with CCA IMT in obese participants. These associations remained significant even after adjustment for triglycerides. APOA5 variants were associated with CCA IMT, particularly in obese participants. The mechanism of these associations and the effect modification by obesity are independent of fasting triglyceride levels.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16474174     DOI: 10.1194/jlr.M500446-JLR200

Source DB:  PubMed          Journal:  J Lipid Res        ISSN: 0022-2275            Impact factor:   5.922


  19 in total

1.  Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

Authors:  Ariel Brautbar; Daniel Covarrubias; John Belmont; Fremiet Lara-Garduno; Salim S Virani; Peter H Jones; Suzanne M Leal; Christie M Ballantyne
Journal:  Atherosclerosis       Date:  2011-08-22       Impact factor: 5.162

2.  APOA5 gene variation modulates the effects of dietary fat intake on body mass index and obesity risk in the Framingham Heart Study.

Authors:  Dolores Corella; Chao-Qiang Lai; Serkalem Demissie; L Adrienne Cupples; Alisa K Manning; Katherine L Tucker; Jose M Ordovas
Journal:  J Mol Med (Berl)       Date:  2007-01-09       Impact factor: 4.599

3.  APOA5 gene variation interacts with dietary fat intake to modulate obesity and circulating triglycerides in a Mediterranean population.

Authors:  Carmen Sánchez-Moreno; Jose M Ordovás; Caren E Smith; Juan C Baraza; Yu-Chi Lee; Marta Garaulet
Journal:  J Nutr       Date:  2011-01-05       Impact factor: 4.798

4.  A single nucleotide polymorphism in APOA5 determines triglyceride levels in Hong Kong and Guangzhou Chinese.

Authors:  Chao Qiang Jiang; Bin Liu; Bernard M Y Cheung; Tai Hing Lam; Jie Ming Lin; Ya Li Jin; Xiao Jun Yue; Kwok Leung Ong; Sidney Tam; Ka Sing Wong; Brian Tomlinson; Karen S L Lam; G Neil Thomas
Journal:  Eur J Hum Genet       Date:  2010-06-23       Impact factor: 4.246

5.  A candidate gene study revealed sex-specific association between the OLR1 gene and carotid plaque.

Authors:  Liyong Wang; Danielle Yanuck; Ashley Beecham; Hannah Gardener; Susan Slifer; Susan H Blanton; Ralph L Sacco; Tatjana Rundek
Journal:  Stroke       Date:  2011-01-21       Impact factor: 7.914

6.  Association of the apolipoprotein A5 gene -1131 T>C polymorphism with fasting blood lipids: a meta-analysis in 37859 subjects.

Authors:  Tongfeng Zhao; Jiangpei Zhao
Journal:  BMC Med Genet       Date:  2010-08-10       Impact factor: 2.103

7.  Apolipoprotein A5 gene C56G variant confers risk for the development of large-vessel associated ischemic stroke.

Authors:  Anita Maász; Péter Kisfali; Zoltán Szolnoki; Ferenc Hadarits; Béla Melegh
Journal:  J Neurol       Date:  2008-02-18       Impact factor: 4.849

Review 8.  The paradox of ApoA5 modulation of triglycerides: evidence from clinical and basic research.

Authors:  Mahdi Garelnabi; Kenton Lor; Jun Jin; Fei Chai; Nalini Santanam
Journal:  Clin Biochem       Date:  2012-09-19       Impact factor: 3.281

Review 9.  Apoprotein A-V: an important regulator of triglyceride metabolism.

Authors:  M Kluger; J Heeren; M Merkel
Journal:  J Inherit Metab Dis       Date:  2008-04-14       Impact factor: 4.982

Review 10.  Clinical significance of apolipoprotein A5.

Authors:  E Shyong Tai; Jose M Ordovas
Journal:  Curr Opin Lipidol       Date:  2008-08       Impact factor: 4.776

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.